Navigation Links
Silence Therapeutics Announces Board Changes and Appointment of New Chief Executive Officer
Date:2/10/2012

Thomas for his many years of valuable service to Silence and wish him well with his future endeavours. I am delighted that Tony has agreed to take on the CEO role. He has impressed us since joining and I am sure he will continue to do so."

Tony Sedgwick, newly promoted Chief Executive Officer, added: "Since joining Silence Therapeutics in September 2011, I have been excited by the Company and the opportunities that lie ahead.   We have a unique proprietary position in RNAi therapeutics and their delivery. I am confident that this will be further strengthened and will be the basis upon which investors and pharmaceutical partners alike will take an increasing interest in this Company. We have already strengthened the business development team with the appointment of Dr Georg Buchner who will now take full responsibility for business development. The Company's pipeline including  Atu027  is making good progress and is endorsed by external partners. I look forward to taking on the role of Chief Executive Officer and working with the staff at Silence to strengthen the Company's pipeline. Over the next few years, I intend to increase the commercial focus of the Company, harness the  RNAi therapeutics  opportunity and, as a result, create substantial'/>"/>

SOURCE Silence Therapeutics Plc
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Silence Therapeutics Additional Listing
2. Silence Therapeutics Announces Positive Response by USPTO that Affirms Validity of Four Foundational RNAi Patents
3. Silence Therapeutics Announces Positive Outcome From Oral Hearing at the European Patent Office
4. Silence Therapeutics Provides Corporate and Development Update
5. Silence Therapeutics Signs Collaboration With Mirna Therapeutics to Evaluate Delivery of Novel microRNA Therapeutics
6. Silence Therapeutics Issued Japanese Patent Covering its Core RNA Interference (RNAi) Technology
7. Silence Therapeutics Lead RNA Interference Therapeutic Prevents Spread of Cancer to Lungs
8. Silence Therapeutics Receives Comprehensive Protection for RNAi Structural Modification Technology in Single European Patent
9. Silence Therapeutics Partner Quark Signs Exclusive Option Agreement With Novartis for Development and Commercialisation of QPI-1002
10. Silence Therapeutics Expands RNAi Structural Modification IP Portfolio With Issuance of New U.S. Patent
11. Silence Therapeutics Issued Novel RNAi Patent Covering High-Value Cancer Target in United States
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2014)... July 11, 2014 /CNW/ - Sunovion Pharmaceuticals Canada Inc. ... (eslicarbazepine acetate) for use as a once-daily adjunctive ... with epilepsy who are not satisfactorily controlled with conventional ... in patients under 18 years of age. ... disorders and according to Epilepsy Canada, it affects 0.6% ...
(Date:7/11/2014)... AZ (PRWEB) July 11, 2014 ... device company specializing in the soft tissue reconstruction ... All-Suture Anchor System for surgeries involving the shoulder ... fixation through a novel, inserter-controlled deployment method. The ... to partial deployment, anchor pull-out, or anchor displacement ...
(Date:7/10/2014)... 10, 2014 Product and process ... low abundance and are often “lost in the ... , Join presenters Dr. Rowel Tobias, Senior Scientist, ... Anders, Head of Quality at Nanotherapeutics, Inc., to ... can speed detection and quantitation while achieving the ...
(Date:7/10/2014)... Understanding the need for better quality ... the gap that currently exists in this area, ChanTest ... portfolio of validated ion channel and GPCR cell lines. ... as ion channels control many critical physiological functions throughout ... the potential to treat a variety of human diseases. ...
Breaking Biology Technology:Sunovion Pharmaceuticals Canada Inc. Announces Health Canada Approval of APTIOM(TM) (eslicarbazepine acetate) as a Once-Daily Adjunctive Treatment for Partial-Onset Seizures in Patients with Epilepsy 2Sunovion Pharmaceuticals Canada Inc. Announces Health Canada Approval of APTIOM(TM) (eslicarbazepine acetate) as a Once-Daily Adjunctive Treatment for Partial-Onset Seizures in Patients with Epilepsy 3Sunovion Pharmaceuticals Canada Inc. Announces Health Canada Approval of APTIOM(TM) (eslicarbazepine acetate) as a Once-Daily Adjunctive Treatment for Partial-Onset Seizures in Patients with Epilepsy 4Cayenne Medical Launches SureLock™ All-Suture Anchor System for Shoulder and Extremity Surgery 2Cayenne Medical Launches SureLock™ All-Suture Anchor System for Shoulder and Extremity Surgery 3Novel Ms Techniques Speed Detection of Biopharmaceutical Product and Process Impurities, New Webinar Hosted by Xtalks 2Leader in Ion Channel Research Announces Newly Validated and Re-Engineered Cells 2Leader in Ion Channel Research Announces Newly Validated and Re-Engineered Cells 3
... product ideas to market, RESEARCH TRIANGLE PARK, N.C., ... to $1 million in loans under,a program unveiled this ... loans are part of an expanded program funded by ... give early-stage,companies a boost before they become competitive for ...
... Nargis, a category 3 tropical storm that struck the low-lying and ... Agriculture Service (FAS) of the U.S. Department of Agriculture (USDA) began ... damaged agricultural areas to accompany its commodity intelligence reports. , ... ...
... July 9 Brinks Hofer Gilson & Lione, one of ... opening,of a new office in the Raleigh/Durham, North Carolina area ... T. Elliott, who will be,based in the Raleigh office. Mr. ... the firm as partners. The office will officially,be open for ...
Cached Biology Technology:N.C. Biotech Center Launches Larger Loans 2Myanmar's Cyclone-Damaged Rice Production Regions Monitored with GIS 2Myanmar's Cyclone-Damaged Rice Production Regions Monitored with GIS 3Brinks Hofer Gilson & Lione Expands to High-Tech Raleigh/Durham Area; Adds Accomplished Patent Attorneys to Its New Office 2Brinks Hofer Gilson & Lione Expands to High-Tech Raleigh/Durham Area; Adds Accomplished Patent Attorneys to Its New Office 3
(Date:7/11/2014)... including scientists from the Max Planck Institute for Medical ... step in understanding photosynthesis, the process by which the ... its atmosphere and which is therefore crucial for all ... researchers report the first direct visualization of a crucial ... which a specific protein complex, photosystem II, splits water ...
(Date:7/11/2014)... risk of kidney injury related to the use of ... of HES molecules, according to a report in ... Anesthesia Research Society (IARS). , The "total mass of ... cultured human renal proximal tubule cells (PTCs), concludes the ... University Hospital Wrzburg, Austria. Other factorssuch as differences ...
(Date:7/11/2014)... is evidence that under the normal circumstances, ... development, maintain neuronal environment, and exhibit therapeutic ... neurodegenerative disease. Previous studies have found that ... after chemical induction have reduced viability, which ... Prof. Xiaodong Yuan, Kailuan General Hospital, Hebei ...
Breaking Biology News(10 mins):A first direct glimpse of photosynthesis in action 2In lab studies, hydroxyethyl starch has direct harmful effects on kidney cells 2
... paper published in the January issue of the journal ... including William A. Masters, a professor at the Friedman School ... new approach to monitoring the relationship between nutrition and child ... of surveys compiled over 20 years, changes in the number ...
... January 31, 2011 A scientist from The Scripps Research Institute ... in preventing blood clot formation. The molecule could become a ... blood clotting diseases such as Hemophilia A. The findings, ... Mosnier, were published in a recent edition of Journal ...
... In order for medical students to ultimately provide quality patient ... teach physiology, one of the core disciplines of medicine, according ... Journal of the American College of Radiology ( www.jacr.org ... systems. "It is vital that medical schools provide ...
Cached Biology News:New approach suggested for monitoring child health in developing countries 2Scripps Research scientist discovers natural molecule indirectly prevents stable clot formation 2Scripps Research scientist discovers natural molecule indirectly prevents stable clot formation 3
... deuterium atoms at the 9, 10, 12, and ... an internal standard for the quantification of 13(S)-HODE ... by incubation of linoleic acid with plant and ... the adhesion of tumor cells to the endothelium ...
...
...
DryStrip aligners, 4. Category: Electrophoresis Systems & Standards & Reagents, IEF & SDS-PAGE & 2-D Electrophoresis, Multiphor II Kits & Components and Accessories....
Biology Products: